Scholarly works in Virology

Permanent URI for this collectionhttps://repository.ui.edu.ng/handle/123456789/514

Browse

Author: search.filters.author.Odaibo, G. N.Subject: search.filters.subject.ART

Search Results

Now showing 1 - 3 of 3
  • Thumbnail Image
    Item
    Baseline CD4 T cell level predicts recovery rate after initiation of art In HIV Infected Nigerians
    (Taylor & Francis Group, 2016) Adewumi, O. M.; Odaibo, G. N.; Olaleye, O. D.
    The most characteristic immunologic disorder in HIV infection is the progressive loss of CD4 Tlymphocytes, thus, it remains the most important and commonly used marker for monitoring ofimmune status of HIV-infected individuals. This study monitored CD4 T lymphocyte cell dynamics among HIV patients on ART, and consequently defined an optimal baseline level required for enhanced ARV treatment. Ninety-eight (M = 33; F = 65) out of 106 consenting HIV-infected ARV-naïve patients enrolled and monitored for 24 months were considered in the analysis. The patients were classified into four groups based on baseline CD4 T lymphocyte cell levels, and specific parameters were evaluated at interval. Median CD4 T lymphocyte increased from 114 (Range: 6–330) at baseline to highest 357 (Range: 15–1036) cells/μL at 18 months of therapy. Fifty (51.0%), 58(59.2%), 75(76.5%), 69(70.4%), 63(64.3%), and 69(70.4%) doubled their preceding CD4 levels during the 3rd, 6th, 9th, 12th, 18th, and 24th months of ART, respectively. Maximum 337, 302, 360, and 475 cells/μL of blood were attained by groups commenced on ART with baseline CD4 ≤ 50, 51–100, 101–200, and 201–350 cells/μL of blood, respectively. The results show that higher baseline CD4 T lymphocyte cell level correlates with enhanced restoration,and plateau after commencement of ART.
  • Thumbnail Image
    Item
    Efficacy of generic highly Active antiretroviral therapy In HIV-1 infected individuals in Nigeria
    (Taylor & Francis, 2015) Adewumi, M. O.; Odaibo, G. N.; Olaleye, O. D.
    CD4 T lymphocyte and plasma HIV RNA parameters have been used to monitor disease progression, and predict clinical course in HIV infection. Initial evaluation of these parameters was conducted in the western countries where accessible ARVs, circulating HIV subtypes and mode of transmission are different from the situation in Nigeria. This study appraised these parameters, and efficacy of generic ARVs. Consenting 106 HIV infected ARV naïve patients were enrolled. CD4 Tlymphocyte and plasma HIV RNA levels were determined at interval for 24 months. Ninety eight (92.5%) of the patients who completed the follow up in strict adherence to therapy guideline were included in the analysis. Baseline median CD4 T lymphocyte increased from 114 (Range: 6–330) to highest 357 (Range: 15–1036) cells/μL at 18 months of therapy, while baseline median plasma viral RNA declined from 4.6 (Range: 2.6–6.0) Log10 copies/mL to undetectable level within three months of therapy. Significant CD4 T-cell restoration and plasma viral RNA decline in the study population demonstrate efficacy of the generic HAART. The importance of combined use of both parameters for evaluation of immunologic and virologic responses to ART was confirmed.
  • Thumbnail Image
    Item
    HBV Infection among HIV-infected cohort And HIV-negative Hospital attendees in South Western Nigeria
    (African Network for Infectious Diseases (ANID), 2014) Adewumi, M. O.; Donbraye, E.; Odaibo, G. N.; Bakarey, A. S.; Opaleye, O. O.; Olaleye, D. O.
    "Background: Prevalence, association and probable mode of acquisition of HBV and HIV dual infections have not been fully explored. Thus, HBV intervention plan and services are sometimes exclusively targeted towards HIV-infected population. We investigated HBV infection among HIV-infected cohort in comparison with HIV-negative hospital attendees to ascertain dual infectivity pattern; thereby encouraging appropriat allotment of intervention services. A total of 349 (M=141; F=208; Mean=33.98 years; Range= 0.33-80 years) plasma specimens from two virus diagnostic laboratories in south-western Nigeria were analysed. These include 182 HIV-positive and 167 HIV-negative specimens from ART and GDV laboratories respectively. The specimens were initially screened for detectable HIV antigen/antibody, and subsequently HBsAg by ELISA technique. Overall, HBsAg was detected in 20.92% (95% CI: 16.65-25.19%) of the patients. Also, 24.82% (95% CI: 17.69 31.95%) and 18.27% (95% CI: 13.02-23.52%) HBsAg positivity was recorded for males and females respectively. CHI square analysis showed no association (P=0.14) between gender and prevalence of HBsAg. Similarly, comparison of prevalence of HBsAg by age groups shows no significant difference (P=0.24). Overall, no significant difference (P=0.59) was observed in the prevalence of HBsAg among the HIV-infected cohort and HIV-negative hospital attendees. Results of the study confirm endemicity and comparable rates of HBV infection independent of HIV-status.